The endocrine function of the heart

Cataliotti group

The main focus of our group is to study the role of hormones produced by the heart during the early stages of human cardiovascular and renal dysfunction.

Starting from the understanding of the existence of an impaired endocrine function of the heart that underlies several cardiovascular and renal diseases in humans, our group investigates the hormonal function of the heart in both physiological and pathophysiological conditions.

The main focus of our group is to study the role of hormones produced by the heart during the early stages of human cardiovascular and renal dysfunction, such as hypertension, stage A-B heart failure, ischemic cardiomyopathy, and mild to moderate renal impairment. Our group has a highly translational approach, performing both clinical studies, and preclinical research using innovative delivery approaches, as well as new therapeutic agents such as alternative forms of natriuretic peptides.

Alessandro Cataliotti is a Professor of Medicine and has joined the University of Oslo at the IEMR three years ago after conducting extensive research in the field of cardiovascular disease in the USA at the prestigious location of the Mayo Clinic Foundation. He has conducted several preclinical and clinical studies to evaluate the effects of cardiac hormones in the setting of cardiovascular and renal dysfunction and has received numerous international scientific awards and nominations in recognition of his work.

Our group is also committed to the discovery of novel small molecules that can enhance the activity of the cardiac peptides, and to further elucidate the mechanisms of actions of molecules known to interfere with the activity of several cardiac hormones.

Group members

Einar Sjaastad Nordén

Doctoral Research Fellow

Gustavo Justo da Silva

Postdoctoral fellow

Henriette Andresen

Doctoral Research Fellow

Raffaele Altara

Postdoctoral fellow

Latest publications

view all >
Zouein FA, Altara R, Massoud GP, Booz GW (2021)
The Angiotensin II Type 1 (AT1) Receptor and Cardiac Hypertrophy: Did we have it wrong all along?
J Cardiovasc Pharmacol
PubMed 33657051 DOI 10.1097/FJC.0000000000000999
Frisk M, Le C, Shen X, Røe ÅT, Hou Y, Manfra O, Silva GJJ, van Hout I, Norden ES, Aronsen JM, Laasmaa M, Espe EKS, Zouein FA, Lambert RR, Dahl CP, Sjaastad I, Lunde IG, Coffey S, Cataliotti A, Gullestad L, Tønnessen T, Jones PP, Altara R, Louch WE (2021)
Etiology-Dependent Impairment of Diastolic Cardiomyocyte Calcium Homeostasis in Heart Failure With Preserved Ejection Fraction
J Am Coll Cardiol, 77 (4), 405-419
PubMed 33509397 DOI 10.1016/j.jacc.2020.11.044
Nordén ES, Bendiksen BA, Andresen H, Bergo KK, Espe EK, Hasic A, Hauge-Iversen IM, Veras I, Hussain RI, Sjaastad I, Christensen G, Cataliotti A (2021)
Sacubitril/valsartan ameliorates cardiac hypertrophy and preserves diastolic function in cardiac pressure overload
ESC Heart Fail, 8 (2), 918-927
PubMed 33497525 DOI 10.1002/ehf2.13177
Tannous C, Booz GW, Altara R, Muhieddine DH, Mericskay M, Refaat MM, Zouein FA (2020)
Nicotinamide adenine dinucleotide: Biosynthesis, consumption and therapeutic role in cardiac diseases
Acta Physiol (Oxf), 231 (3), e13551
PubMed 32853469 DOI 10.1111/apha.13551
Booz GW, Altara R, Eid AH, Wehbe Z, Fares S, Zaraket H, Habeichi NJ, Zouein FA (2020)
Macrophage responses associated with COVID-19: A pharmacological perspective
Eur J Pharmacol, 887, 173547
PubMed 32919938 DOI 10.1016/j.ejphar.2020.173547
view all >